Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Scambia

Showing results (341-350 of 551) with videos related to

Pageof 56
Sort By:
Current Pharmaceutical Design|January 31, 2015
Treating cancer in older and oldest old patientsG Colloca, A Corsonello, E Marzetti, et al.
Cancer Treatment Reviews|October 11, 2021
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitorsM Bartoletti, L Musacchio, G Giannone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancerG Scambia, P B Panici, L Pierelli, et al.
Gene Therapy|September 23, 2000
Transfected human dendritic cells to induce antitumor immunityA Rughetti, M Biffoni, M Sabbatucci, et al.
Cancer Letters|November 12, 1996
Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanismA Ercoli, G Scambia, R De Vincenzo, et al.
Cancer Treatment Reviews|June 1, 1989
Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-lookP Benedetti Panici, G Scambia, S Greggi, et al.
Cancer Detection and Prevention|January 1, 1989
Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patientsG Mantovani, F G Serri, A Macciò, et al.
European Review for Medical and Pharmacological Sciences|June 5, 2020
The interplay between immune system and microbiota in gynecological diseases: a narrative reviewP Villa, C Cipolla, S D'Ippolito, et al.
Journal of Cancer Research and Clinical Oncology|February 11, 2023
Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter studyA Rosati, V Vargiu, C Certelli, et al.
Cancer|June 1, 1988
Effects of antiestrogen and progestin on immune functions in breast cancer patientsG Scambia, P B Panici, A Maccio, et al.
Pageof 56

Showing results (341-350 of 551) with videos related to

Sort By:
Pageof 56
Current Pharmaceutical Design|January 31, 2015
Treating cancer in older and oldest old patientsG Colloca, A Corsonello, E Marzetti, et al.
Cancer Treatment Reviews|October 11, 2021
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitorsM Bartoletti, L Musacchio, G Giannone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancerG Scambia, P B Panici, L Pierelli, et al.
Gene Therapy|September 23, 2000
Transfected human dendritic cells to induce antitumor immunityA Rughetti, M Biffoni, M Sabbatucci, et al.
Cancer Letters|November 12, 1996
Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanismA Ercoli, G Scambia, R De Vincenzo, et al.
Cancer Treatment Reviews|June 1, 1989
Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-lookP Benedetti Panici, G Scambia, S Greggi, et al.
Cancer Detection and Prevention|January 1, 1989
Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patientsG Mantovani, F G Serri, A Macciò, et al.
European Review for Medical and Pharmacological Sciences|June 5, 2020
The interplay between immune system and microbiota in gynecological diseases: a narrative reviewP Villa, C Cipolla, S D'Ippolito, et al.
Journal of Cancer Research and Clinical Oncology|February 11, 2023
Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter studyA Rosati, V Vargiu, C Certelli, et al.
Cancer|June 1, 1988
Effects of antiestrogen and progestin on immune functions in breast cancer patientsG Scambia, P B Panici, A Maccio, et al.
Pageof 56